nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—Fatigue—Etoposide—testicular cancer	0.000763	0.000763	CcSEcCtD
Betaxolol—Neuropathy peripheral—Epirubicin—testicular cancer	0.000763	0.000763	CcSEcCtD
Betaxolol—Stomatitis—Epirubicin—testicular cancer	0.000758	0.000758	CcSEcCtD
Betaxolol—Pain—Etoposide—testicular cancer	0.000757	0.000757	CcSEcCtD
Betaxolol—Constipation—Etoposide—testicular cancer	0.000757	0.000757	CcSEcCtD
Betaxolol—Conjunctivitis—Epirubicin—testicular cancer	0.000756	0.000756	CcSEcCtD
Betaxolol—Dysuria—Doxorubicin—testicular cancer	0.000755	0.000755	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.00075	0.00075	CcSEcCtD
Betaxolol—Sweating—Epirubicin—testicular cancer	0.000746	0.000746	CcSEcCtD
Betaxolol—Dizziness—Ifosfamide—testicular cancer	0.000741	0.000741	CcSEcCtD
Betaxolol—Pharyngitis—Methotrexate—testicular cancer	0.000741	0.000741	CcSEcCtD
Betaxolol—Weight increased—Doxorubicin—testicular cancer	0.000735	0.000735	CcSEcCtD
Betaxolol—Epistaxis—Epirubicin—testicular cancer	0.000734	0.000734	CcSEcCtD
Betaxolol—Weight decreased—Doxorubicin—testicular cancer	0.00073	0.00073	CcSEcCtD
Betaxolol—Sinusitis—Epirubicin—testicular cancer	0.00073	0.00073	CcSEcCtD
Betaxolol—Feeling abnormal—Etoposide—testicular cancer	0.000729	0.000729	CcSEcCtD
Betaxolol—Hyperglycaemia—Doxorubicin—testicular cancer	0.000728	0.000728	CcSEcCtD
Betaxolol—Nausea—Dactinomycin—testicular cancer	0.000727	0.000727	CcSEcCtD
Betaxolol—Agranulocytosis—Epirubicin—testicular cancer	0.000726	0.000726	CcSEcCtD
Betaxolol—Pneumonia—Doxorubicin—testicular cancer	0.000724	0.000724	CcSEcCtD
Betaxolol—Infestation NOS—Doxorubicin—testicular cancer	0.00072	0.00072	CcSEcCtD
Betaxolol—Infestation—Doxorubicin—testicular cancer	0.00072	0.00072	CcSEcCtD
Betaxolol—Visual impairment—Methotrexate—testicular cancer	0.000719	0.000719	CcSEcCtD
Betaxolol—Vomiting—Ifosfamide—testicular cancer	0.000713	0.000713	CcSEcCtD
Betaxolol—Hypersensitivity—Cisplatin—testicular cancer	0.000712	0.000712	CcSEcCtD
Betaxolol—Bradycardia—Epirubicin—testicular cancer	0.000711	0.000711	CcSEcCtD
Betaxolol—Rash—Ifosfamide—testicular cancer	0.000707	0.000707	CcSEcCtD
Betaxolol—Dermatitis—Ifosfamide—testicular cancer	0.000706	0.000706	CcSEcCtD
Betaxolol—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000706	0.000706	CcSEcCtD
Betaxolol—Urticaria—Etoposide—testicular cancer	0.000703	0.000703	CcSEcCtD
Betaxolol—Stomatitis—Doxorubicin—testicular cancer	0.000702	0.000702	CcSEcCtD
Betaxolol—Rhinitis—Epirubicin—testicular cancer	0.0007	0.0007	CcSEcCtD
Betaxolol—Body temperature increased—Etoposide—testicular cancer	0.0007	0.0007	CcSEcCtD
Betaxolol—Conjunctivitis—Doxorubicin—testicular cancer	0.0007	0.0007	CcSEcCtD
Betaxolol—Eye disorder—Methotrexate—testicular cancer	0.000697	0.000697	CcSEcCtD
Betaxolol—Tinnitus—Methotrexate—testicular cancer	0.000696	0.000696	CcSEcCtD
Betaxolol—Hypoaesthesia—Epirubicin—testicular cancer	0.000695	0.000695	CcSEcCtD
Betaxolol—Asthenia—Cisplatin—testicular cancer	0.000693	0.000693	CcSEcCtD
Betaxolol—Pharyngitis—Epirubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Betaxolol—Cardiac disorder—Methotrexate—testicular cancer	0.000693	0.000693	CcSEcCtD
Betaxolol—Sweating—Doxorubicin—testicular cancer	0.00069	0.00069	CcSEcCtD
Betaxolol—Epistaxis—Doxorubicin—testicular cancer	0.000679	0.000679	CcSEcCtD
Betaxolol—Angiopathy—Methotrexate—testicular cancer	0.000677	0.000677	CcSEcCtD
Betaxolol—Sinusitis—Doxorubicin—testicular cancer	0.000675	0.000675	CcSEcCtD
Betaxolol—Immune system disorder—Methotrexate—testicular cancer	0.000674	0.000674	CcSEcCtD
Betaxolol—Visual impairment—Epirubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Betaxolol—Mediastinal disorder—Methotrexate—testicular cancer	0.000673	0.000673	CcSEcCtD
Betaxolol—Agranulocytosis—Doxorubicin—testicular cancer	0.000672	0.000672	CcSEcCtD
Betaxolol—Chills—Methotrexate—testicular cancer	0.00067	0.00067	CcSEcCtD
Betaxolol—Nausea—Ifosfamide—testicular cancer	0.000666	0.000666	CcSEcCtD
Betaxolol—Diarrhoea—Cisplatin—testicular cancer	0.000661	0.000661	CcSEcCtD
Betaxolol—Alopecia—Methotrexate—testicular cancer	0.00066	0.00066	CcSEcCtD
Betaxolol—Bradycardia—Doxorubicin—testicular cancer	0.000658	0.000658	CcSEcCtD
Betaxolol—Mental disorder—Methotrexate—testicular cancer	0.000654	0.000654	CcSEcCtD
Betaxolol—Eye disorder—Epirubicin—testicular cancer	0.000653	0.000653	CcSEcCtD
Betaxolol—Hypersensitivity—Etoposide—testicular cancer	0.000652	0.000652	CcSEcCtD
Betaxolol—Tinnitus—Epirubicin—testicular cancer	0.000651	0.000651	CcSEcCtD
Betaxolol—Malnutrition—Methotrexate—testicular cancer	0.00065	0.00065	CcSEcCtD
Betaxolol—Erythema—Methotrexate—testicular cancer	0.00065	0.00065	CcSEcCtD
Betaxolol—Cardiac disorder—Epirubicin—testicular cancer	0.000648	0.000648	CcSEcCtD
Betaxolol—Flushing—Epirubicin—testicular cancer	0.000648	0.000648	CcSEcCtD
Betaxolol—Rhinitis—Doxorubicin—testicular cancer	0.000648	0.000648	CcSEcCtD
Betaxolol—Hypoaesthesia—Doxorubicin—testicular cancer	0.000643	0.000643	CcSEcCtD
Betaxolol—Pharyngitis—Doxorubicin—testicular cancer	0.000641	0.000641	CcSEcCtD
Betaxolol—Dysgeusia—Methotrexate—testicular cancer	0.000636	0.000636	CcSEcCtD
Betaxolol—Asthenia—Etoposide—testicular cancer	0.000635	0.000635	CcSEcCtD
Betaxolol—Angiopathy—Epirubicin—testicular cancer	0.000634	0.000634	CcSEcCtD
Betaxolol—Immune system disorder—Epirubicin—testicular cancer	0.000631	0.000631	CcSEcCtD
Betaxolol—Mediastinal disorder—Epirubicin—testicular cancer	0.000629	0.000629	CcSEcCtD
Betaxolol—Chills—Epirubicin—testicular cancer	0.000627	0.000627	CcSEcCtD
Betaxolol—Pruritus—Etoposide—testicular cancer	0.000626	0.000626	CcSEcCtD
Betaxolol—Arrhythmia—Epirubicin—testicular cancer	0.000624	0.000624	CcSEcCtD
Betaxolol—Visual impairment—Doxorubicin—testicular cancer	0.000623	0.000623	CcSEcCtD
Betaxolol—Alopecia—Epirubicin—testicular cancer	0.000617	0.000617	CcSEcCtD
Betaxolol—Vomiting—Cisplatin—testicular cancer	0.000614	0.000614	CcSEcCtD
Betaxolol—Vision blurred—Methotrexate—testicular cancer	0.000612	0.000612	CcSEcCtD
Betaxolol—Mental disorder—Epirubicin—testicular cancer	0.000612	0.000612	CcSEcCtD
Betaxolol—Rash—Cisplatin—testicular cancer	0.000609	0.000609	CcSEcCtD
Betaxolol—Dermatitis—Cisplatin—testicular cancer	0.000609	0.000609	CcSEcCtD
Betaxolol—Malnutrition—Epirubicin—testicular cancer	0.000608	0.000608	CcSEcCtD
Betaxolol—Erythema—Epirubicin—testicular cancer	0.000608	0.000608	CcSEcCtD
Betaxolol—Diarrhoea—Etoposide—testicular cancer	0.000606	0.000606	CcSEcCtD
Betaxolol—Eye disorder—Doxorubicin—testicular cancer	0.000604	0.000604	CcSEcCtD
Betaxolol—Ill-defined disorder—Methotrexate—testicular cancer	0.000603	0.000603	CcSEcCtD
Betaxolol—Tinnitus—Doxorubicin—testicular cancer	0.000603	0.000603	CcSEcCtD
Betaxolol—Anaemia—Methotrexate—testicular cancer	0.0006	0.0006	CcSEcCtD
Betaxolol—Flushing—Doxorubicin—testicular cancer	0.0006	0.0006	CcSEcCtD
Betaxolol—Cardiac disorder—Doxorubicin—testicular cancer	0.0006	0.0006	CcSEcCtD
Betaxolol—Tension—Epirubicin—testicular cancer	0.000597	0.000597	CcSEcCtD
Betaxolol—Dysgeusia—Epirubicin—testicular cancer	0.000595	0.000595	CcSEcCtD
Betaxolol—Nervousness—Epirubicin—testicular cancer	0.000591	0.000591	CcSEcCtD
Betaxolol—Angiopathy—Doxorubicin—testicular cancer	0.000586	0.000586	CcSEcCtD
Betaxolol—Malaise—Methotrexate—testicular cancer	0.000586	0.000586	CcSEcCtD
Betaxolol—Dizziness—Etoposide—testicular cancer	0.000585	0.000585	CcSEcCtD
Betaxolol—Muscle spasms—Epirubicin—testicular cancer	0.000585	0.000585	CcSEcCtD
Betaxolol—Immune system disorder—Doxorubicin—testicular cancer	0.000584	0.000584	CcSEcCtD
Betaxolol—Vertigo—Methotrexate—testicular cancer	0.000584	0.000584	CcSEcCtD
Betaxolol—Mediastinal disorder—Doxorubicin—testicular cancer	0.000582	0.000582	CcSEcCtD
Betaxolol—Chills—Doxorubicin—testicular cancer	0.00058	0.00058	CcSEcCtD
Betaxolol—Arrhythmia—Doxorubicin—testicular cancer	0.000577	0.000577	CcSEcCtD
Betaxolol—Nausea—Cisplatin—testicular cancer	0.000574	0.000574	CcSEcCtD
Betaxolol—Vision blurred—Epirubicin—testicular cancer	0.000573	0.000573	CcSEcCtD
Betaxolol—Alopecia—Doxorubicin—testicular cancer	0.000571	0.000571	CcSEcCtD
Betaxolol—Cough—Methotrexate—testicular cancer	0.000567	0.000567	CcSEcCtD
Betaxolol—Mental disorder—Doxorubicin—testicular cancer	0.000566	0.000566	CcSEcCtD
Betaxolol—Ill-defined disorder—Epirubicin—testicular cancer	0.000564	0.000564	CcSEcCtD
Betaxolol—Vomiting—Etoposide—testicular cancer	0.000563	0.000563	CcSEcCtD
Betaxolol—Malnutrition—Doxorubicin—testicular cancer	0.000563	0.000563	CcSEcCtD
Betaxolol—Erythema—Doxorubicin—testicular cancer	0.000563	0.000563	CcSEcCtD
Betaxolol—Anaemia—Epirubicin—testicular cancer	0.000562	0.000562	CcSEcCtD
Betaxolol—Rash—Etoposide—testicular cancer	0.000558	0.000558	CcSEcCtD
Betaxolol—Dermatitis—Etoposide—testicular cancer	0.000558	0.000558	CcSEcCtD
Betaxolol—Headache—Etoposide—testicular cancer	0.000555	0.000555	CcSEcCtD
Betaxolol—Chest pain—Methotrexate—testicular cancer	0.000553	0.000553	CcSEcCtD
Betaxolol—Arthralgia—Methotrexate—testicular cancer	0.000553	0.000553	CcSEcCtD
Betaxolol—Myalgia—Methotrexate—testicular cancer	0.000553	0.000553	CcSEcCtD
Betaxolol—Tension—Doxorubicin—testicular cancer	0.000552	0.000552	CcSEcCtD
Betaxolol—Dysgeusia—Doxorubicin—testicular cancer	0.000551	0.000551	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000549	0.000549	CcSEcCtD
Betaxolol—Malaise—Epirubicin—testicular cancer	0.000548	0.000548	CcSEcCtD
Betaxolol—Discomfort—Methotrexate—testicular cancer	0.000546	0.000546	CcSEcCtD
Betaxolol—Nervousness—Doxorubicin—testicular cancer	0.000546	0.000546	CcSEcCtD
Betaxolol—Vertigo—Epirubicin—testicular cancer	0.000546	0.000546	CcSEcCtD
Betaxolol—Syncope—Epirubicin—testicular cancer	0.000545	0.000545	CcSEcCtD
Betaxolol—Muscle spasms—Doxorubicin—testicular cancer	0.000541	0.000541	CcSEcCtD
Betaxolol—Palpitations—Epirubicin—testicular cancer	0.000537	0.000537	CcSEcCtD
Betaxolol—Confusional state—Methotrexate—testicular cancer	0.000535	0.000535	CcSEcCtD
Betaxolol—Loss of consciousness—Epirubicin—testicular cancer	0.000534	0.000534	CcSEcCtD
Betaxolol—Cough—Epirubicin—testicular cancer	0.000531	0.000531	CcSEcCtD
Betaxolol—Vision blurred—Doxorubicin—testicular cancer	0.00053	0.00053	CcSEcCtD
Betaxolol—Infection—Methotrexate—testicular cancer	0.000527	0.000527	CcSEcCtD
Betaxolol—Nausea—Etoposide—testicular cancer	0.000526	0.000526	CcSEcCtD
Betaxolol—Ill-defined disorder—Doxorubicin—testicular cancer	0.000522	0.000522	CcSEcCtD
Betaxolol—Nervous system disorder—Methotrexate—testicular cancer	0.00052	0.00052	CcSEcCtD
Betaxolol—Anaemia—Doxorubicin—testicular cancer	0.00052	0.00052	CcSEcCtD
Betaxolol—Thrombocytopenia—Methotrexate—testicular cancer	0.000519	0.000519	CcSEcCtD
Betaxolol—Myalgia—Epirubicin—testicular cancer	0.000518	0.000518	CcSEcCtD
Betaxolol—Chest pain—Epirubicin—testicular cancer	0.000518	0.000518	CcSEcCtD
Betaxolol—Arthralgia—Epirubicin—testicular cancer	0.000518	0.000518	CcSEcCtD
Betaxolol—Anxiety—Epirubicin—testicular cancer	0.000516	0.000516	CcSEcCtD
Betaxolol—Skin disorder—Methotrexate—testicular cancer	0.000515	0.000515	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000514	0.000514	CcSEcCtD
Betaxolol—Hyperhidrosis—Methotrexate—testicular cancer	0.000513	0.000513	CcSEcCtD
Betaxolol—Discomfort—Epirubicin—testicular cancer	0.000511	0.000511	CcSEcCtD
Betaxolol—Malaise—Doxorubicin—testicular cancer	0.000507	0.000507	CcSEcCtD
Betaxolol—Dry mouth—Epirubicin—testicular cancer	0.000506	0.000506	CcSEcCtD
Betaxolol—Vertigo—Doxorubicin—testicular cancer	0.000505	0.000505	CcSEcCtD
Betaxolol—Anorexia—Methotrexate—testicular cancer	0.000505	0.000505	CcSEcCtD
Betaxolol—Syncope—Doxorubicin—testicular cancer	0.000505	0.000505	CcSEcCtD
Betaxolol—Confusional state—Epirubicin—testicular cancer	0.0005	0.0005	CcSEcCtD
Betaxolol—Palpitations—Doxorubicin—testicular cancer	0.000497	0.000497	CcSEcCtD
Betaxolol—Oedema—Epirubicin—testicular cancer	0.000496	0.000496	CcSEcCtD
Betaxolol—Hypotension—Methotrexate—testicular cancer	0.000495	0.000495	CcSEcCtD
Betaxolol—Loss of consciousness—Doxorubicin—testicular cancer	0.000494	0.000494	CcSEcCtD
Betaxolol—Infection—Epirubicin—testicular cancer	0.000493	0.000493	CcSEcCtD
Betaxolol—Cough—Doxorubicin—testicular cancer	0.000491	0.000491	CcSEcCtD
Betaxolol—Shock—Epirubicin—testicular cancer	0.000488	0.000488	CcSEcCtD
Betaxolol—Nervous system disorder—Epirubicin—testicular cancer	0.000487	0.000487	CcSEcCtD
Betaxolol—Thrombocytopenia—Epirubicin—testicular cancer	0.000486	0.000486	CcSEcCtD
Betaxolol—Tachycardia—Epirubicin—testicular cancer	0.000484	0.000484	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000483	0.000483	CcSEcCtD
Betaxolol—Skin disorder—Epirubicin—testicular cancer	0.000482	0.000482	CcSEcCtD
Betaxolol—Hyperhidrosis—Epirubicin—testicular cancer	0.00048	0.00048	CcSEcCtD
Betaxolol—Insomnia—Methotrexate—testicular cancer	0.00048	0.00048	CcSEcCtD
Betaxolol—Chest pain—Doxorubicin—testicular cancer	0.000479	0.000479	CcSEcCtD
Betaxolol—Arthralgia—Doxorubicin—testicular cancer	0.000479	0.000479	CcSEcCtD
Betaxolol—Myalgia—Doxorubicin—testicular cancer	0.000479	0.000479	CcSEcCtD
Betaxolol—Anxiety—Doxorubicin—testicular cancer	0.000477	0.000477	CcSEcCtD
Betaxolol—Paraesthesia—Methotrexate—testicular cancer	0.000476	0.000476	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000476	0.000476	CcSEcCtD
Betaxolol—Discomfort—Doxorubicin—testicular cancer	0.000473	0.000473	CcSEcCtD
Betaxolol—Anorexia—Epirubicin—testicular cancer	0.000473	0.000473	CcSEcCtD
Betaxolol—Dyspnoea—Methotrexate—testicular cancer	0.000473	0.000473	CcSEcCtD
Betaxolol—Dry mouth—Doxorubicin—testicular cancer	0.000468	0.000468	CcSEcCtD
Betaxolol—Dyspepsia—Methotrexate—testicular cancer	0.000467	0.000467	CcSEcCtD
Betaxolol—Hypotension—Epirubicin—testicular cancer	0.000464	0.000464	CcSEcCtD
Betaxolol—Confusional state—Doxorubicin—testicular cancer	0.000463	0.000463	CcSEcCtD
Betaxolol—Decreased appetite—Methotrexate—testicular cancer	0.000461	0.000461	CcSEcCtD
Betaxolol—Oedema—Doxorubicin—testicular cancer	0.000459	0.000459	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000458	0.000458	CcSEcCtD
Betaxolol—Fatigue—Methotrexate—testicular cancer	0.000457	0.000457	CcSEcCtD
Betaxolol—Infection—Doxorubicin—testicular cancer	0.000456	0.000456	CcSEcCtD
Betaxolol—Pain—Methotrexate—testicular cancer	0.000453	0.000453	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000452	0.000452	CcSEcCtD
Betaxolol—Shock—Doxorubicin—testicular cancer	0.000452	0.000452	CcSEcCtD
Betaxolol—Nervous system disorder—Doxorubicin—testicular cancer	0.00045	0.00045	CcSEcCtD
Betaxolol—Thrombocytopenia—Doxorubicin—testicular cancer	0.00045	0.00045	CcSEcCtD
Betaxolol—Insomnia—Epirubicin—testicular cancer	0.000449	0.000449	CcSEcCtD
Betaxolol—Tachycardia—Doxorubicin—testicular cancer	0.000448	0.000448	CcSEcCtD
Betaxolol—Skin disorder—Doxorubicin—testicular cancer	0.000446	0.000446	CcSEcCtD
Betaxolol—Paraesthesia—Epirubicin—testicular cancer	0.000446	0.000446	CcSEcCtD
Betaxolol—Hyperhidrosis—Doxorubicin—testicular cancer	0.000444	0.000444	CcSEcCtD
Betaxolol—Dyspnoea—Epirubicin—testicular cancer	0.000442	0.000442	CcSEcCtD
Betaxolol—Anorexia—Doxorubicin—testicular cancer	0.000438	0.000438	CcSEcCtD
Betaxolol—Feeling abnormal—Methotrexate—testicular cancer	0.000437	0.000437	CcSEcCtD
Betaxolol—Dyspepsia—Epirubicin—testicular cancer	0.000437	0.000437	CcSEcCtD
Betaxolol—Decreased appetite—Epirubicin—testicular cancer	0.000431	0.000431	CcSEcCtD
Betaxolol—Hypotension—Doxorubicin—testicular cancer	0.000429	0.000429	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000428	0.000428	CcSEcCtD
Betaxolol—Fatigue—Epirubicin—testicular cancer	0.000428	0.000428	CcSEcCtD
Betaxolol—Constipation—Epirubicin—testicular cancer	0.000424	0.000424	CcSEcCtD
Betaxolol—Pain—Epirubicin—testicular cancer	0.000424	0.000424	CcSEcCtD
Betaxolol—Urticaria—Methotrexate—testicular cancer	0.000421	0.000421	CcSEcCtD
Betaxolol—Body temperature increased—Methotrexate—testicular cancer	0.000419	0.000419	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000418	0.000418	CcSEcCtD
Betaxolol—Insomnia—Doxorubicin—testicular cancer	0.000415	0.000415	CcSEcCtD
Betaxolol—Paraesthesia—Doxorubicin—testicular cancer	0.000412	0.000412	CcSEcCtD
Betaxolol—Dyspnoea—Doxorubicin—testicular cancer	0.000409	0.000409	CcSEcCtD
Betaxolol—Feeling abnormal—Epirubicin—testicular cancer	0.000409	0.000409	CcSEcCtD
Betaxolol—Dyspepsia—Doxorubicin—testicular cancer	0.000404	0.000404	CcSEcCtD
Betaxolol—Decreased appetite—Doxorubicin—testicular cancer	0.000399	0.000399	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000396	0.000396	CcSEcCtD
Betaxolol—Fatigue—Doxorubicin—testicular cancer	0.000396	0.000396	CcSEcCtD
Betaxolol—Urticaria—Epirubicin—testicular cancer	0.000394	0.000394	CcSEcCtD
Betaxolol—Constipation—Doxorubicin—testicular cancer	0.000393	0.000393	CcSEcCtD
Betaxolol—Pain—Doxorubicin—testicular cancer	0.000393	0.000393	CcSEcCtD
Betaxolol—Body temperature increased—Epirubicin—testicular cancer	0.000392	0.000392	CcSEcCtD
Betaxolol—Hypersensitivity—Methotrexate—testicular cancer	0.000391	0.000391	CcSEcCtD
Betaxolol—Asthenia—Methotrexate—testicular cancer	0.00038	0.00038	CcSEcCtD
Betaxolol—Feeling abnormal—Doxorubicin—testicular cancer	0.000378	0.000378	CcSEcCtD
Betaxolol—Pruritus—Methotrexate—testicular cancer	0.000375	0.000375	CcSEcCtD
Betaxolol—Hypersensitivity—Epirubicin—testicular cancer	0.000366	0.000366	CcSEcCtD
Betaxolol—Urticaria—Doxorubicin—testicular cancer	0.000365	0.000365	CcSEcCtD
Betaxolol—Body temperature increased—Doxorubicin—testicular cancer	0.000363	0.000363	CcSEcCtD
Betaxolol—Diarrhoea—Methotrexate—testicular cancer	0.000363	0.000363	CcSEcCtD
Betaxolol—Asthenia—Epirubicin—testicular cancer	0.000356	0.000356	CcSEcCtD
Betaxolol—Pruritus—Epirubicin—testicular cancer	0.000351	0.000351	CcSEcCtD
Betaxolol—Dizziness—Methotrexate—testicular cancer	0.000351	0.000351	CcSEcCtD
Betaxolol—Diarrhoea—Epirubicin—testicular cancer	0.00034	0.00034	CcSEcCtD
Betaxolol—Hypersensitivity—Doxorubicin—testicular cancer	0.000338	0.000338	CcSEcCtD
Betaxolol—Vomiting—Methotrexate—testicular cancer	0.000337	0.000337	CcSEcCtD
Betaxolol—Rash—Methotrexate—testicular cancer	0.000334	0.000334	CcSEcCtD
Betaxolol—Dermatitis—Methotrexate—testicular cancer	0.000334	0.000334	CcSEcCtD
Betaxolol—Headache—Methotrexate—testicular cancer	0.000332	0.000332	CcSEcCtD
Betaxolol—Asthenia—Doxorubicin—testicular cancer	0.000329	0.000329	CcSEcCtD
Betaxolol—Dizziness—Epirubicin—testicular cancer	0.000328	0.000328	CcSEcCtD
Betaxolol—Pruritus—Doxorubicin—testicular cancer	0.000325	0.000325	CcSEcCtD
Betaxolol—Vomiting—Epirubicin—testicular cancer	0.000316	0.000316	CcSEcCtD
Betaxolol—Nausea—Methotrexate—testicular cancer	0.000315	0.000315	CcSEcCtD
Betaxolol—Diarrhoea—Doxorubicin—testicular cancer	0.000314	0.000314	CcSEcCtD
Betaxolol—Rash—Epirubicin—testicular cancer	0.000313	0.000313	CcSEcCtD
Betaxolol—Dermatitis—Epirubicin—testicular cancer	0.000313	0.000313	CcSEcCtD
Betaxolol—Headache—Epirubicin—testicular cancer	0.000311	0.000311	CcSEcCtD
Betaxolol—Dizziness—Doxorubicin—testicular cancer	0.000304	0.000304	CcSEcCtD
Betaxolol—Nausea—Epirubicin—testicular cancer	0.000295	0.000295	CcSEcCtD
Betaxolol—Vomiting—Doxorubicin—testicular cancer	0.000292	0.000292	CcSEcCtD
Betaxolol—Rash—Doxorubicin—testicular cancer	0.000289	0.000289	CcSEcCtD
Betaxolol—Dermatitis—Doxorubicin—testicular cancer	0.000289	0.000289	CcSEcCtD
Betaxolol—Headache—Doxorubicin—testicular cancer	0.000288	0.000288	CcSEcCtD
Betaxolol—Nausea—Doxorubicin—testicular cancer	0.000273	0.000273	CcSEcCtD
